[
  {
    "ts": "2026-02-17T13:00:00+00:00",
    "headline": "ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026",
    "summary": "LONDON, February 17, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February.",
    "url": "https://finance.yahoo.com/news/viiv-healthcare-showcases-long-acting-130000162.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "8800bcec-3dde-3b18-8d3a-37da6a6ce043",
      "content": {
        "id": "8800bcec-3dde-3b18-8d3a-37da6a6ce043",
        "contentType": "STORY",
        "title": "ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026",
        "description": "",
        "summary": "LONDON, February 17, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced data presentations from its innovative HIV treatment and prevention portfolio and integrase inhibitor (INSTI)-led pipeline at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado from 22-25 February.",
        "pubDate": "2026-02-17T13:00:00Z",
        "displayTime": "2026-02-17T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/6f4fb020fe518bebbee1a057829a94c8",
          "originalWidth": 480,
          "originalHeight": 409,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LtBPNmY5pPKY_s5M2QqY7Q--~B/aD00MDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6f4fb020fe518bebbee1a057829a94c8.cf.webp",
              "width": 480,
              "height": 409,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rVljpwgmsKp59ocnLEPq6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6f4fb020fe518bebbee1a057829a94c8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viiv-healthcare-showcases-long-acting-130000162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viiv-healthcare-showcases-long-acting-130000162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "SGIOF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T11:45:00+00:00",
    "headline": "Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer",
    "summary": "NEW YORK, February 17, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically si",
    "url": "https://finance.yahoo.com/news/pfizer-braftovi-regimen-improves-progression-114500018.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "a669505c-45f0-37c2-9ff3-ce947c09ac1c",
      "content": {
        "id": "a669505c-45f0-37c2-9ff3-ce947c09ac1c",
        "contentType": "STORY",
        "title": "Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer",
        "description": "",
        "summary": "NEW YORK, February 17, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The BRAFTOVI regimen demonstrated a statistically si",
        "pubDate": "2026-02-17T11:45:00Z",
        "displayTime": "2026-02-17T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/b751fc2f7dd4c5d463e36ed4db929077",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2o2uM3NzoWVgSVeIjwA3VQ--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b751fc2f7dd4c5d463e36ed4db929077.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p4NslNQRhqRcSvHcmsyVmg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b751fc2f7dd4c5d463e36ed4db929077.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-braftovi-regimen-improves-progression-114500018.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-braftovi-regimen-improves-progression-114500018.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T13:09:58+00:00",
    "headline": "Pfizer Trial Updates Test Investor Views On Pipeline And Valuation",
    "summary": "Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal cancer with BRAF V600E mutation. The company also announced Phase 2b data for its once monthly, ultra long acting GLP 1 obesity drug candidate. The FDA granted Priority Review to Pfizer’s supplemental Biologics License Application for HYMPAVZI, seeking expanded use in hemophilia patients. For you as an investor, these updates touch three areas where Pfizer is highly...",
    "url": "https://finance.yahoo.com/news/pfizer-trial-updates-test-investor-130958650.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3e802e6d-cd7c-3765-a463-adc4667b21c2",
      "content": {
        "id": "3e802e6d-cd7c-3765-a463-adc4667b21c2",
        "contentType": "STORY",
        "title": "Pfizer Trial Updates Test Investor Views On Pipeline And Valuation",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal cancer with BRAF V600E mutation. The company also announced Phase 2b data for its once monthly, ultra long acting GLP 1 obesity drug candidate. The FDA granted Priority Review to Pfizer’s supplemental Biologics License Application for HYMPAVZI, seeking expanded use in hemophilia patients. For you as an investor, these updates touch three areas where Pfizer is highly...",
        "pubDate": "2026-02-17T13:09:58Z",
        "displayTime": "2026-02-17T13:09:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-trial-updates-test-investor-130958650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-trial-updates-test-investor-130958650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-17T16:04:36+00:00",
    "headline": "Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk",
    "summary": "Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.",
    "url": "https://www.investors.com/news/technology/hims-stock-compounded-semaglutide-oral-novo-nordisk-fda/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "c4ab0c64-09af-388e-a321-56dbd64c2866",
      "content": {
        "id": "c4ab0c64-09af-388e-a321-56dbd64c2866",
        "contentType": "STORY",
        "title": "Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk",
        "description": "",
        "summary": "Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.",
        "pubDate": "2026-02-17T16:04:36Z",
        "displayTime": "2026-02-17T16:04:36Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/c4ab0c64-09af-388e-a321-56dbd64c2866/hims-hers-faces-new-hurdle.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/a25a163db3ec3a190106ca8c665184de",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WQaD7ik_eMrnRSclzUE_9w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/a25a163db3ec3a190106ca8c665184de.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LnM4Pd9H7PIZMmWx6zQOaA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/a25a163db3ec3a190106ca8c665184de.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/hims-stock-compounded-semaglutide-oral-novo-nordisk-fda/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "VKTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]